Symbols

PTHS

Pelthos Therapeutics·AMEX

--(--)

PTHS fundamentals

PTHS Q4 2025 Earnings

Pelthos Therapeutics (PTHS) released its earnings on Mar 19, 2026: revenue was 10.00M (YoY --), missed estimates; EPS was -3.76 (YoY --), missed estimates.

Revenue / YoY

10.00M

EPS / YoY

-3.76

Report date

Mar 19, 2026

PTHS Earnings Call Summary for Q4,2025

ZELSUVMI Success: 129% prescription growth (Q3 to Q4 2025) and 28% revenue increase, with 99% Medicaid coverage.
New Product Acquisitions: Xepi (impetigo) and Xeglyze (lice) set for 2027 launches, enhancing commercial leverage.
Financial Improvement: 22% reduction in operating loss, $18M cash balance, and $30M term debt for 2026 growth.
Profitability Outlook: ZELSUVMI expected to turn profitable by end-2026, with GTN margins stabilizing at mid-30%.

Earnings

EPS

Revenue

Revenue & Expenses

PTHS has released its 2025 Q4 earnings report, with revenue of 9.39M, reflecting a YoY change of NaN%, and net profit of -21.66M, showing a YoY change of -1024.82%. The Sankey diagram below clearly presents PTHS's revenue sources and cost distribution.

Key Indicators

Pelthos Therapeutics (PTHS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Pelthos Therapeutics (PTHS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Pelthos Therapeutics (PTHS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Pelthos Therapeutics (PTHS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown